結節性皮膚炎疫苗市場規模、佔有率和成長分析：按疫苗類型、給藥途徑、目標動物、最終用戶和地區分類－2026-2033年產業預測

2024年全球結節性皮斑病疫苗市場價值為27億美元，預計2025年將成長至28.4億美元，到2033年將成長至41.9億美元。預測期（2026-2033年）的複合年成長率預計為5.0%。

全球結節性皮癬菌疫苗市場的主要驅動力是牛中該疾病發病率的上升和地理範圍的擴大，這促使人們需要加強預防措施和疫苗接種。該市場涵蓋多種疫苗類型，例如活病毒疫苗疫苗和去活化疫苗，以及大規模免疫宣傳活動的物流和服務支援。疫情爆發會導致嚴重的生產損失、貿易限制和動物福利問題。從區域性應變轉向跨區域協調免疫接種，促使亞洲和歐洲等地區加強監測系統建置和改善低溫運輸物流。製造商正在投資研發耐熱的單劑量製劑，以簡化現場接種流程。人工智慧技術進一步最佳化了監測和分發，提高了檢測效率，並確保及時接種疫苗，最終推動了市場成長。

推動全球結節性皮膚病疫苗市場發展的因素

結節性皮癬菌疫苗的需求主要受流行地區擴大免疫宣傳活動的推動。這些努力有助於有效分配資源，提高獸醫服務的參與度，並優先考慮牛的免疫接種，從而提高疫苗接種率。政府和援助組織的支持在加強低溫運輸基礎設施、發展人力資源和改善推廣活動方面發揮著至關重要的作用，有助於將疫苗廣泛分發給農民。精簡的物流和有組織的群體免疫接種活動有助於消除獲取障礙，增強人們對免疫接種效果的信心，最終促進公共和私營部門持續開展宣傳活動運動並簽訂採購合約。反過來，這又促進了市場的永續成長，並鼓勵生產者提高產能。

全球皮膚結節疫苗市場的限制因素

監管核准的複雜性和延誤給新型結節性皮膚病疫苗的及時上市帶來了重大挑戰。這些複雜性延長了評估週期，並為研發人員帶來了不確定性。此外，各國不同的註冊要求和申請預期可能需要進行廣泛的實地調查並收集更多數據，這增加了資源需求，並可能對中小型生產者造成阻礙。漫長的核准流程也會進一步阻礙疫苗採購和接種計畫的實施，削弱疫苗上市的勢頭，並限制生產商的獲利能力。這種不確定性會抑制研發投入，導致改良疫苗無法及時送達受影響最嚴重的地區。

結節性皮膚病疫苗的全球市場趨勢

全球結節性皮癬菌疫苗市場正呈現顯著的在地化生產能力提升趨勢。生產商優先考慮在疫區附近建造生產設施，以提高應對力和供應鏈韌性。這一策略轉變不僅減少了對遠端供應商的依賴，也促進了與當地企業和政府的合作。透過投資技術轉移和人力資源開發，企業能夠有效率地擴大疫苗生產規模，適應區域病原菌株的特性，並應對不同的監管環境。這些努力正在推動獸醫服務領域的疫苗應用，並透過在市場中創造本地化價值來促進永續成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢

全球結節性皮斑病疫苗市場規模：按疫苗類型和複合年成長率分類（2026-2033 年）

• 減毒活病毒疫苗
• 去活化疫苗
• 重組疫苗

全球結節性皮斑病疫苗市場規模：依給藥途徑及複合年成長率分類（2026-2033 年）

• 肌肉內注射
• 皮下注射
• 口服

全球結節性皮癬菌疫苗市場規模：按目標動物和複合年成長率 (2026-2033) 分類

• 牛
• 水牛
• 其他

全球結節性皮斑病疫苗市場規模：按最終用戶和複合年成長率分類（2026-2033 年）

• 動物醫院
• 畜牧業的棋子
• 研究機構

結節性皮膚增生疫苗的全球市場規模和複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• Zoetis
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Virbac
• Ceva Sante Animale
• Oxford Immunotec
• Vetoquinol
• Huvepharma
• iO Veterinary
• Algenex
• MSD Animal Health
• AgriLabs
• Intervet
• Bioniche Animal Health
• KindredBio
• Indian Immunologicals Ltd.
• Adimmune Corporation
• Biovac
• Kye Pharmaceuticals

結論與建議

Global Lumpy Skin Disease Vaccines Market size was valued at USD 2.7 Billion in 2024 and is poised to grow from USD 2.84 Billion in 2025 to USD 4.19 Billion by 2033, growing at a CAGR of 5.0% during the forecast period (2026-2033).

The global market for lumpy skin disease vaccines is primarily driven by the increasing incidence and geographic spread of outbreaks among cattle, necessitating enhanced preventive measures and vaccination responses. This market includes various vaccine types such as live attenuated and inactivated formulations alongside logistical and service support for mass immunization campaigns. Outbreaks lead to substantial production losses, trade restrictions, and animal welfare issues. The evolution from localized responses to coordinated transregional vaccination efforts illustrates growing efforts in regions like Asia and Europe, with a focus on enhanced surveillance and improved cold chain logistics. Manufacturers are investing in thermostable, single-dose formulations for simpler field deployment. AI technology is further optimizing surveillance and distribution, enhancing detection efficiency, and ensuring timely vaccination, ultimately facilitating market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lumpy Skin Disease Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lumpy Skin Disease Vaccines Market Segments Analysis

Global lumpy skin disease vaccines market is segmented by vaccine type, administration route, target animal, end-user and region. Based on vaccine type, the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines and Recombinant Vaccines. Based on administration route, the market is segmented into Intramuscular, Subcutaneous and Oral. Based on target animal, the market is segmented into Cattle, Buffalo and Others. Based on end-user, the market is segmented into Veterinary Clinics, Livestock Farmers and Research Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lumpy Skin Disease Vaccines Market

The demand for lumpy skin disease vaccines is significantly driven by the expansion of vaccination campaigns in regions where the disease is endemic. These initiatives effectively coordinate resources, involve veterinary services, and prioritize the immunization of cattle, leading to increased vaccine uptake. Support from governments and donors plays a crucial role in enhancing cold chain infrastructure, training personnel, and improving outreach, which facilitates wider distribution of vaccines to farmers. Streamlined logistics and organized mass vaccination efforts help eliminate access barriers and foster trust in vaccination results, ultimately encouraging repeat campaigns and procurement commitments from both public and private sectors, thus promoting ongoing market growth and motivating manufacturers to enhance production capacities.

Restraints in the Global Lumpy Skin Disease Vaccines Market

The complexities and delays associated with regulatory approvals pose significant challenges to the timely introduction of new lumpy skin disease vaccines. These intricacies extend evaluation periods and create uncertainty for developers. Additionally, varying national registration requirements and differing dossier expectations demand extensive local studies or supplementary data, which increases resource demands and can deter smaller manufacturers. Protracted authorization processes further hinder procurement and the implementation of vaccination programs, diminishing the momentum for adoption and restricting manufacturers' revenue potential. Such uncertainty may discourage investment in research and development, consequently delaying the availability of enhanced vaccines to the regions most impacted.

Market Trends of the Global Lumpy Skin Disease Vaccines Market

The Global Lumpy Skin Disease Vaccines market is witnessing a notable trend towards localized manufacturing capacity. As manufacturers seek to enhance their responsiveness and supply chain resilience, they are prioritizing production facilities closer to affected regions. This strategic shift not only reduces reliance on distant suppliers but also fosters collaborations with local firms and governments. By investing in technology transfer and workforce development, companies are scaling vaccine production efficiently, addressing regional strain profiles, and navigating varied regulatory landscapes. These initiatives are driving adoption among veterinary services and promoting sustainable growth through localized value creation in the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Lumpy Skin Disease Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Live Attenuated Vaccines
• Inactivated Vaccines
• Recombinant Vaccines

Global Lumpy Skin Disease Vaccines Market Size by Administration Route & CAGR (2026-2033)

• Market Overview
• Intramuscular
• Subcutaneous
• Oral

Global Lumpy Skin Disease Vaccines Market Size by Target Animal & CAGR (2026-2033)

• Market Overview
• Cattle
• Buffalo
• Others

Global Lumpy Skin Disease Vaccines Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Veterinary Clinics
• Livestock Farmers
• Research Institutions

Global Lumpy Skin Disease Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Administration Route, Target Animal, End-User)
  • US
  • Canada
• Europe (Vaccine Type, Administration Route, Target Animal, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Administration Route, Target Animal, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Administration Route, Target Animal, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Administration Route, Target Animal, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Immunotec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huvepharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• iO Veterinary
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Algenex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AgriLabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioniche Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KindredBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adimmune Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kye Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations